Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis
Harrington J, Hellkamp A, Mahaffey K, Breithardt G, Halperin J, Hankey G, Becker R, Nessel C, Berkowitz S, Fox K, Singer D, Goodman S, Patel M, Piccini J. Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis. Journal Of The American Heart Association 2024, 13: e028951. PMID: 38780169, PMCID: PMC11255646, DOI: 10.1161/jaha.122.028951.Peer-Reviewed Original ResearchAtrial fibrillationROCKET AFClinical trialsEnd pointsLow overall event ratesInternational double-blindClinical trials of interventionsRandomized clinical trialsAssessment of dayOverall event rateDouble-blindAnticoagulation trialsTreatment armsIncreased riskWarfarinTrials of interventionsClinical utilityTreatment groupsEvent ratesPatientsDAOHPoisson regressionComorbiditiesFibrillationTrialsFactor XI: structure, function and therapeutic inhibition
Ali A, Becker R. Factor XI: structure, function and therapeutic inhibition. Journal Of Thrombosis And Thrombolysis 2024, 1-14. PMID: 38622277, DOI: 10.1007/s11239-024-02972-5.Peer-Reviewed Original ResearchFactor XI inhibitorsVitamin K antagonistsEnd-stage renal diseaseFactor XITraditional anticoagulantsSafety profileInherent risk of bleedingPhase 3 clinical trialsPhase 2 studyMultiple coagulation factorsRisk of bleedingFactor XI deficiencyIntrinsic pathway of coagulationPathway of coagulationFXI inhibitorsK antagonistsOral anticoagulantsAnticoagulant therapyTherapeutic anticoagulationVenous thromboembolismPreclinical studiesAtrial fibrillationClinical endpointsRenal diseaseClinical trials